SCHEMBL6798722

SCHEMBL6798722

CCOC(=O)c1cc(C(=O)NCc2cccc3ccccc23)ccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
PKM P14618 1/20 0.48
CYP2C19 P33261 1/20 0.48
CSNK1D P48730 1/20 0.48
CA2 P00918 1/20 0.47
CYP2C9 P11712 2/20 0.46
LMNA P02545 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
NQO2 P16083 2/20 0.44
CDC25B P30305 1/20 0.43
CHRNB2 P17787 1/20 0.43
CHRNA4 P43681 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
F12 P00748 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213910 0.86 CA2 (0.54) MAPTCYP1A2CYP3A4CYP2D6PKM
SCHEMBL6798961 0.84 CYP2C9 (0.54) MAPTCYP1A2CYP3A4CYP2D6PKM
SCHEMBL4684457 0.83 MAPT (0.47) MAPTCYP1A2CYP3A4CYP2D6PKM
SCHEMBL28967781 0.80 CYP2C9 (0.54) MAPTCYP1A2CYP3A4CYP2D6PKM
SCHEMBL30253543 0.80 CYP2C9 (0.54) MAPTCYP1A2CYP3A4CYP2D6PKM
SCHEMBL19632249 0.79 CDC25B (0.48) MAPTLMNAALDH1A1HPGDCDC25B
SCHEMBL28967801 0.79 CYP2C9 (0.53) MAPTCYP1A2CYP3A4CYP2D6PKM
SCHEMBL30253736 0.79 CYP2C9 (0.53) MAPTCYP1A2CYP3A4CYP2D6PKM
Hydrochloric Acid SCHEMBL28967775 0.79 CYP2C9 (0.53) MAPTCYP1A2CYP3A4CYP2D6PKM
Hydrochloric Acid SCHEMBL30253848 0.79 CYP2C9 (0.53) MAPTCYP1A2CYP3A4CYP2D6PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040097508-A1 Novel heterocyclically substituted amides, their preparation and use ABBOTT GMBH & CO. KG (DE) 2004-05-20 US disclosed
US-6630493-B1 Inhibitors of capain enzymes useful for the treatment of ischemias of the heart, the kidney or of central nervous system (e.g. \"stroke\"), inflammations, muscular dystrophy, cataracts of the eyes, Alzheimer's disease etc. BASF AKTIENGESELLSCHAFT (DE) 2003-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097508-A1 Novel heterocyclically substituted amides, their preparation and use CAPN1, CAPNS1, CAPN2 MAPT 18/4885CYP1A2 2635/4885CYP3A4 1904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.